Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen

NCT04549025 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
69
Enrollment
INDUSTRY
Sponsor class

Stopped The Sponsor decided to discontinue development of pimivalimab prior to the planned study completion. At the time of the decision to discontinue development, enrollment in the study had been completed.

Conditions

Interventions

Sponsor

Jounce Therapeutics, Inc.